- Home
- ATIF vs RDHL Comparison
ATIF vs RDHL Comparison
Compare ATIF & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATIF
- RDHL
- Stock Information
- Founded
- ATIF 2015
- RDHL 2009
- Country
- ATIF United States
- RDHL Israel
- Employees
- ATIF N/A
- RDHL N/A
- Industry
- ATIF Professional Services
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- ATIF Consumer Discretionary
- RDHL Health Care
- Exchange
- ATIF Nasdaq
- RDHL Nasdaq
- Market Cap
- ATIF 8.9M
- RDHL 8.6M
- IPO Year
- ATIF 2019
- RDHL N/A
- Fundamental
- Price
- ATIF $0.64
- RDHL $7.00
- Analyst Decision
- ATIF
- RDHL
- Analyst Count
- ATIF 0
- RDHL 0
- Target Price
- ATIF N/A
- RDHL N/A
- AVG Volume (30 Days)
- ATIF 364.5K
- RDHL 21.0K
- Earning Date
- ATIF 12-31-2024
- RDHL 12-27-2024
- Dividend Yield
- ATIF N/A
- RDHL N/A
- EPS Growth
- ATIF N/A
- RDHL N/A
- EPS
- ATIF N/A
- RDHL N/A
- Revenue
- ATIF $620,000.00
- RDHL $3,707,000.00
- Revenue This Year
- ATIF N/A
- RDHL $224.90
- Revenue Next Year
- ATIF N/A
- RDHL $82.69
- P/E Ratio
- ATIF N/A
- RDHL N/A
- Revenue Growth
- ATIF N/A
- RDHL N/A
- 52 Week Low
- ATIF $0.58
- RDHL $6.35
- 52 Week High
- ATIF $1.50
- RDHL $43.50
- Technical
- Relative Strength Index (RSI)
- ATIF 43.99
- RDHL 42.48
- Support Level
- ATIF $0.70
- RDHL $7.09
- Resistance Level
- ATIF $1.25
- RDHL $7.44
- Average True Range (ATR)
- ATIF 0.10
- RDHL 0.51
- MACD
- ATIF 0.01
- RDHL -0.03
- Stochastic Oscillator
- ATIF 6.39
- RDHL 10.31
About ATIF ATIF Holdings Limited
ATIF Holdings Ltd is a consulting company. It provides financial and advisory services to small and medium-sized enterprises and also to individual customers and families. The firm also offers Pre-IPO's, and Post-IPO's services. It operates in one operating segment which is the consulting service business. It generates the majority of its revenue from the USA.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.